No increased cancer risk seen in long-term Lantus trial
This article was originally published in Scrip
Executive Summary
The longest, five-year, randomised controlled study comparing Sanofi-Aventis's long-acting, once-daily insulin analogue Lantus (insulin glargine) with human NPH (neutral protamine Hagedorn) insulin has not shown a higher incidence of cancer with Lantus, and similar effects on diabetic retinopathy, which the company hopes will quell some of the concerns raised by the recent publication of data from patient registries in several European countries that linked the blockbuster drug with a higher incidence of cancer (scripnews.com. June 30th, 2009).